{"member_organisations": "Inga organisationer som medlemmar. Bara enskilda forskande l\u00e4kemedelsf\u00f6retag.", "identification_number": "544344129150-31", "fields_of_interest": "Trade, Business and Industry, Research and innovation, Public Health", "head_office_address": "L\u00e4kemedelsindustrif\u00f6reningen", "full_time_equivalent_fte": "0,5", "person_with_legal_responsibility": "Anders Blanck", "inter_groups": "", "financial_year_start_date": "01/01/2016", "grants": "", "head_office_country": "Sweden", "eu_initiatives": "EU Pharmaceutical Incentives Analysis.  \nBrexit.  \nEMAs flyttning fr\u00e5n London till Amsterdam.  \nIMI.", "organisation_name": "L\u00e4kemedelsindustrif\u00f6reningen (LIF)", "belgium_office_post_code": "", "number_of_persons_involved": "2", "procurement": "", "section": "II - In-house lobbyists and trade/business/professional associations", "source": "", "belgium_office_address": "", "subsection": "Trade and business associations", "belgium_office_phone": "", "number_of_ep_accredited_persons": "", "overall_budget_turnover_as_a_range": "", "belgium_office_city": "", "persons_accredited_for_access_to_european_parliament_premises": "", "estimate_of_costs_absolute_amount": "", "registration_date": "05/12/2017", "website_address": "http://www.lif.se", "commission_expert_groups_and_other_similar_entities_european_commission": "NA", "head_office_post_box": "17608", "head_office_city": "Stockholm", "membership": "Svenskt N\u00e4ringsliv \nEFPIA \nAESGP", "head_office_post_code": "11892", "goals__remit": "LIF -  de forskande l\u00e4kemedelsf\u00f6retagen i Sverige, verkar f\u00f6r patientens r\u00e4tt till h\u00f6gkvalitativ v\u00e5rd vilket vi vill n\u00e5 via n\u00e4ra och konstruktiva samarbeten och diskussioner med v\u00e5rdens olika akt\u00f6rer samt politiker, tj\u00e4nstem\u00e4n och patientf\u00f6retr\u00e4dare.", "industry_forums": "", "head_office_phone": "(+46)84623700", "level_of_interest": "national", "relevant_communication": "Informationsm\u00f6ten med svenska EU-parlamentariker om EU Pharmaceutical Incentives Analysis.", "financial_year_end_date": "01/12/2016", "estimate_of_costs_as_a_range": "0-9999", "overall_budget_turnover_absolute_amount": "0", "legal_status": "F\u00f6rening", "person_in_charge_of_eu_relations": "Anders Blanck", "customers": "", "belgium_office_post_box": "", "position": "Generalsekreterare"}